Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lactated Ringer's Versus Normal Saline for Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03642769
Recruitment Status : Recruiting
First Posted : August 22, 2018
Last Update Posted : May 22, 2019
Sponsor:
Information provided by (Responsible Party):
James Buxbaum, University of Southern California

Brief Summary:

Acute pancreatitis is a common problem in the United States necessitating 275,000 hospital admissions per year, with resultant healthcare costs of approximately 2.5 billion USD annually. As numerous trials have failed to show a benefit to specific pharmacologic therapies in acute pancreatitis, the mainstay of treatment has been both supportive care and early, aggressive fluid resuscitation. Small randomized studies have shown conflicting results with regards to the influence of resuscitation fluid on outcomes in acute pancreatitis, necessitating a large randomized trial to clarify if fluid choice matters or not in the treatment of acute pancreatitis.

The objective of this study is to assess the comparative efficacy of normal saline versus lactated ringer's solution in the management of acute pancreatitis.

Patients presenting to the Los Angeles County Hospital with acute pancreatitis will be randomized to fluid resuscitation with NS or LR with volumes of fluid administered according to a pre-determined algorithm that will be the same for both treatment arms.

The primary outcome of the study will be the change in SIRS prevalence from enrollment to 24 hours. Secondary outcomes will include the change in SIRS prevalence from enrollment to 48 hours and 72 hours, development of moderately severe or severe pancreatitis, change in PASS score, ICU admission, length of hospitalization, persistent pain or disability after discharge, and time of advancement to oral diet and discharge.


Condition or disease Intervention/treatment Phase
Pancreatitis, Acute Other: Fluid administration Not Applicable

Detailed Description:

Background: Acute pancreatitis is a common problem in the United States necessitating 275,000 hospital admissions per year, with resultant healthcare costs of approximately 2.5 billion USD annually. As numerous trials have failed to show a benefit to specific pharmacologic therapies in acute pancreatitis, the mainstay of treatment has been both supportive care and early, aggressive fluid resuscitation. Small randomized studies have shown conflicting results with regards to the influence of resuscitation fluid on outcomes in acute pancreatitis, necessitating a large randomized trial to clarify if fluid choice matters or not in the treatment of acute pancreatitis.

Objective: To assess the comparative efficacy of normal saline versus lactated ringer's solution in the management of acute pancreatitis.

Study Design: Patients presenting to the Los Angeles County Hospital with acute pancreatitis are the focus population of this study. Patients will be randomized to fluid resuscitation with NS or LR within 8 hours of diagnosis of pancreatitis. The inclusion and exclusion criterion will be assessed (see below). Randomization will be performed using a random sequence algorithm with concealed allocation. The patients will be blinded to allocation by covering the bag with an opaque covering. A study physician determining the outcomes will also be blinded. Following randomization, the volumes of fluid administered for the resuscitation will be determined by a pre-determined algorithm that will be the same for both treatment arms. The hydration algorithm is as follows: all patients will receive a bolus of the treatment fluid at a rate of 5 mL/kg/hour to be administered over the first two hours (total 10 mL/kg) with an assessment for volume overload at 1 hour. They will then will receive maintenance fluids at a rate of 3 mL/kg/hour. After 12 hours participants will have blood urea nitrogen (BUN) assessed, which is part of the standard clinical procedure. Those who do not have a fall in this parameter or who develop SIRS by this 12 hour checkpoint will receive a second 5 mL/kg/hour bolus over two hours (as above) of their designated treatment fluid followed by further treatment fluid at a rate of 3 mL/kg/hour. Those who do have a fall in BUN will receive further treatment fluid at a rate of 3 mL/kg/hour for 12 additional hours. Patients' volume status will be assessed in the following manner: study physicians will perform a targeted physical exam which will include assessment of JVD, lung auscultation, and monitoring for edema Q12 hours for the first 24 hours, then daily for the remainder of the hospital admission. In elderly patients and those with co-morbidities, the targeted physical exam will be performed Q12 hours for the entire hospital admission. Vitals will also be obtained Q6-8 hours. If they develop signs of fluid overload including pitting edema, ascites, anasacra, pulmonary edema, or dyspnea, or signs of renal failure including oliguria, anuria, or hypotension, they will have their fluid rate managed at the discretion of their treating physicians. However, it will be requested that if further fluid is given that it be the assigned type (LR versus NS). At 24 hours patients will be assessed for SIRS development (see outcomes). Beyond this point fluid rate will be per the primary team though it still be encouraged that the assigned type of fluid (LR versus NS) is used for additional resuscitation with the rate and volume beyond this point at the discretion of the treating physician. However, if the treating physicians have a strong preference to change to a different fluid type for clinical reasons this will be recorded (for post hoc analysis) and the patient included in the intention to treat analysis.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 119 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Lactated Ringer's Versus Normal Saline in the Management of Acute Pancreatitis
Actual Study Start Date : September 18, 2018
Estimated Primary Completion Date : February 25, 2020
Estimated Study Completion Date : February 25, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Arm Intervention/treatment
Active Comparator: Lactated Ringer
Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
Other: Fluid administration
Fluid administration of bolus and maintenance fluids
Other Name: Fluid

Experimental: Normal Saline
Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
Other: Fluid administration
Fluid administration of bolus and maintenance fluids
Other Name: Fluid




Primary Outcome Measures :
  1. SIRS at 24 hours [ Time Frame: 24 hours ]
    Change in SIRS prevalence from enrollment to 24 hours


Secondary Outcome Measures :
  1. SIRS at 48 hours [ Time Frame: 48 hours ]
    Proportion of patients with change in SIRS from enrollment to 48 hours

  2. SIRS at 72 hours [ Time Frame: 72 hours ]
    Change in SIRS prevalence from enrollment to 72 hours

  3. Moderately severe acute pancreatitis [ Time Frame: 48 hours ]
    Development of moderately severe acute pancreatitis

  4. Severe acute pancreatitis [ Time Frame: >48 hours ]
    Development of severe acute pancreatitis

  5. PASS score [ Time Frame: 24 hours ]
    Change in PASS score from enrollment to 24 hours

  6. PASS score [ Time Frame: 48 hours ]
    Change in PASS score from enrollment to 48 hours

  7. PASS score [ Time Frame: 72 hours ]
    Change in PASS score from enrollment to 72 hours

  8. ICU admission [ Time Frame: >72 hours ]
    ICU admission and ICU intervention including intubation, respiratory distress with out intubation defined as RR>20 AND O2 Sat<90% on room air, death, development of extrapancreatic fluid collection (EPFS)

  9. Length of hospitalization [ Time Frame: >72 hours ]
    Length of hospitalization

  10. Pain after discharge based on a 0-10 intensity scale (10 most severe, 0 none) [ Time Frame: 2 weeks ]
    Report of persistent pain or disability after discharge based on telephone follow-up based on a 0-10 intensity scale (10 most severe, 0 none)

  11. Advance diet [ Time Frame: >48 hours ]
    Time to advancement of oral diet

  12. Time to work [ Time Frame: 2 weeks ]
    Time to work after hospitalization based on post-discharge telephone follow-up



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Presentation with acute pancreatitis as defined by two of three criterion; amylase or lipase > 3x the upper limit of normal, classical abdominal pain, or imaging suggestive of pancreatitis. Such radiographic findings include swelling, edema, or heterogeneity of the gland or peripancreatic fluid or stranding.

Exclusion Criteria:

  • Patients with severe pancreatitis as defined by the Revised Atlanta Classification will be excluded. Severe pancreatitis is defined by the Revised Atlanta Classification as those with a Modified Marshall score of >2 for their cardiovascular renal, or respiratory system will be excluded (Figure 2).13 Practically this includes patients with systolic blood pressure <90, serum creatinine >1.9, and PaO2/FiO2 <300 (Figure 3). Since blood gases are unlikely to be drawn on those with mild pancreatitis we will exclude patients with an oxygen saturation <92% on room air and certainly any patients which require intubation for respiratory failure due to pancreatitis.
  • Patients who cannot tolerate increased doses of fluids for other reasons will also be excluded. This consists of those with cardiac insufficiency (CI, >NYHA Class II heart failure), pulmonary edema, dialysis requirement, or severe liver dysfunction (albumin < 3mg/dL, known cirrhosis).
  • Pregnant women will also be excluded as they are prone to retain sodium and water, which puts them at increased risk of pulmonary congestion, ascites or peripheral edema.
  • Patients who are incarcerated, younger than eighteen, or unable to give informed consent will be excluded.
  • Individuals who present with clinical signs of edema or anasacra, including pulmonary congestion, peripheral swelling, and ascites, will also be ineligible for the study.
  • Administration of fluids prior to the enrollment in the study will not be an exclusion criterion as this reflects actual clinical practice (hydration during evaluation period) however all fluids given prior to the study will be meticulously recorded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03642769


Contacts
Layout table for location contacts
Contact: James Buxbaum, MD 1 323 409 5371 james.buxbaum@med.usc.edu

Locations
Layout table for location information
United States, California
LAC+USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: James Buxbaum, MD         
Sponsors and Collaborators
University of Southern California
Investigators
Layout table for investigator information
Principal Investigator: James Buxbaum, MD University of Southern California
  Study Documents (Full-Text)

Documents provided by James Buxbaum, University of Southern California:
Study Protocol  [PDF] July 11, 2018


Publications:

Layout table for additonal information
Responsible Party: James Buxbaum, Principal Investigator, University of Southern California
ClinicalTrials.gov Identifier: NCT03642769     History of Changes
Other Study ID Numbers: APP-17-06494
First Posted: August 22, 2018    Key Record Dates
Last Update Posted: May 22, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by James Buxbaum, University of Southern California:
Pancreatitis
Fluids
SIRS
Management
Lactated Ringer
Normal Saline
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatitis
Pancreatic Diseases
Digestive System Diseases